Probe of Alibaba Unearthed Evidence of Intentional Sale of Dangerous Drugs to U.S. Consumers, Yet DOJ Chose No Prosecution
Probe of Alibaba unearthed evidence it knowingly – The Probe of Alibaba unearthed evidence suggesting the company knowingly allowed harmful medications to be sold to American consumers through its e-commerce platform. This revelation, based on internal documents and public records, has raised questions about corporate responsibility and regulatory oversight. For over a decade, Alibaba Group and its U.S.-based payment gateway partner facilitated the distribution of counterfeit, adulterated, and mislabeled drugs, with employees repeatedly flagging compliance concerns. Despite these warnings, the companies continued to permit the sale of products that posed serious health risks, prompting a critical examination of their accountability measures.
As the Probe of Alibaba progressed, federal investigators amassed substantial data showing a systematic pattern of negligence. The evidence included communication between Alibaba executives and sellers about the quality of pharmaceutical items, as well as internal audits highlighting recurring issues. Under the Trump administration, prosecutors believed the case warranted felony charges under the Food, Drug and Cosmetic Act, which has been in effect since 1938 and governs the safety of medical products. However, the DOJ’s decision to pursue a non-prosecution agreement instead of criminal charges has drawn scrutiny, with critics arguing that the companies’ actions warranted stronger legal action.
The resolution of the Probe of Alibaba involved a settlement that totaled $600 million in penalties. This agreement, finalized during the Biden administration, required the company to admit to lesser misdemeanor violations rather than felony offenses. While the settlement addressed financial accountability, it left many unanswered questions about the company’s intent and the severity of the harm caused to U.S. consumers. Insiders have described the outcome as “beyond disappointing,” emphasizing that the evidence clearly demonstrated Alibaba’s awareness of the risks associated with the drugs it permitted to be sold.
“There was egregious conduct by a Chinese-owned company. An NPA is not even a slap on the wrist,” said an anonymous source, reflecting on the case’s significance. The statement underscores the gap between the companies’ actions and the DOJ’s response, with critics questioning whether the settlement adequately reflects the scale of the violation.”
Broader Trends in Corporate Enforcement
The Probe of Alibaba is part of a growing trend where corporate offenders face leniency in the face of significant health and safety risks. In recent years, the DOJ has shifted its focus toward settlements and civil penalties, often sidelining criminal prosecutions. This pattern has been evident in cases such as the recall of defective CPAP machines and the contamination crisis at a U.S. baby formula plant, both of which resulted in over $1 billion in settlements. These decisions have sparked debates about whether the DOJ is prioritizing financial penalties over true accountability.
Since 2022, federal prosecutors in Philadelphia and Washington, D.C., have investigated a Philips subsidiary after millions of devices were recalled due to faulty foam that released potentially carcinogenic chemicals. The Probe of Alibaba and this Philips case share similarities in that both highlight how corporate giants can exploit regulatory loopholes to continue selling unsafe products. The DOJ’s reliance on non-prosecution agreements in such instances has led to accusations that it is using prosecutorial discretion to shield large companies from the full consequences of their actions.
Legal experts and consumer advocates argue that the Probe of Alibaba demonstrates a broader pattern of under-enforcement. Lisa Gilbert of Public Citizen pointed out the contradiction between Trump’s emphasis on criminal justice and the DOJ’s apparent preference for settlements. “Withholding accountability in cases that impact Americans’ health and safety has real-life consequences,” she said, stressing that the decision to not prosecute undermines public trust in regulatory bodies. The case also raises concerns about how the DOJ defines “willful” misconduct, with some suggesting the standard is too lenient for companies that repeatedly ignore warnings.
